m
Recent Posts
Connect with:
Wednesday / December 11.
HomeminewsPremium ‘Max’ CLs Launched by Johnson and Johnson

Premium ‘Max’ CLs Launched by Johnson and Johnson

Australians will soon have more options when it comes to daily contact lenses following the launch of Johnson and Johnson’s Acuvue Oasys Max 1-Day contact lenses (CLs) and Acuvue Oasys Max 1-Day multifocal CLs.

With adults spending an average of 13+ hours looking at screens daily,1 placing increasing demand on our eyes, Johnson and Johnson said the lenses arrive at a pivotal time.

Described as “an unprecedented combination of new technologies” that provide “reliable comfort and performance”, Acuvue Oasys Max 1-Day lenses are built with TearStable Technology to maximise tear-film stability and lock in moisture for exceptional all-day comfort,2 while an OptiBlue light filter with the highest level blue-violet light filter in the industry at 60%‡,3 helps reduce light scatter and increase visual clarity, day and night. Additionally, Acuvue Oasys Max 1-Day lenses block 99.9% UVA rays and 100% UVB rays.††,§§,4,5

Michelle Ho, Business Unit Director, Vision, Johnson and Johnson, Australia and New Zealand said there is “a huge need for innovation like Acuvue Oasys Max 1-Day, that has been informed by wearers and eye care professionals, priming it to keep up with the lifestyles of all Australians, and address eye strain as a result of longer days and increased time looking at digital devices”.

Johnson and Johnson said the lenses arrive at a pivotal time.

Presbyopia Solution

For patients with presbyopia, Johnson and Johnson claims its new Acuvue Oasys Max 1-Day multifocal CLs provide crisp, clear vision at all distances and in all lighting conditions, as well as all-day comfort.7 The lenses combine the same two powerful technologies – TearStable Technology and the OptiBlue light filter – plus Pupil Optimised Design technology, which tailors 100% of parameters to pupil size variations across both age and refraction compared to less than 2% for the leading competitor, for exceptionally effortless vision.§,6 This is the same technology that is available across all Acuvue Multifocal CLs.7

Building on an Unbeaten Portfolio

Acuvue Oasys Max 1-Day builds on the Acuvue Oasys portfolio of products, which is unbeaten in comfort across 29 clinical studies.‡‡ In clinical trials of Acuvue Oasys Max 1-Day, nearly 90% of wearers reported all-day comfort and a reduction in tired eyes from digital devices, and nearly 100% agreed the lenses provided clear, reliable vision.2

The lenses will be available to wearers in Australia from 1 July 2024.

 

 

‡ Versus publicly available knowledge as of December 2023.

†† Helps protect against transmission of harmful UV radiation to the cornea and into the eye.

§ Warning: UV-absorbing contact lenses are the NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. Wearers should continue to use UV-absorbing eyewear as directed. Note: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities). UV-blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-blocking contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your eye care practitioner for more information.

§ Compared to competitor’s designs, technology optimised for both the parameters of refractive error and add power.

‡‡ ClinicalTrials.gov is a website maintained by the NIH. The 29 clinical studies evaluated subjective comfort as a primary or secondary endpoint for Acuvue Oasys brand 2-week family, Acuvue Oasys 1-Day Brand family, and Acuvue Oasys Max 1-Day brand family of contact lenses, vs. competitors’ products. Review conducted as of April 2024.

References

  1. Eyesafe estimate based upon Nielsen Q3 2019 Total Audience Report. Available at:eyesafe.com/covid-19-screen-time-spike-to-over-13-hours-per-day.
  2. JJV data on file, 2022. CSM subjective responses Acuvue Oasys Max 1-Day contact lenses: retrospective meta-analysis.
  3. JJV data on file 2022. TearStable technology definition.
  4. JJV data on file Material properties: 1-Day Acuvue Moist, 1-Day Acuvue Trueye, Acuvue Oasys 1-Day with HydraLuxe technology and Acuvue Oasys Max 1-Day with TearStable technology brand contact lenses.
  5. JJV data on file 2022: Master brand claims on clinical performance and overall material properties for Acuvue brand soft contact lenses.
  6. JJV data on file 2022. Subjective stand-alone claims for Acuvue Oasys Max 1-Day multifocal contact lenses – exploratory meta-analysis.
  7. JJV data on file 2022. CSM: Acuvue Pupil Optimized Design technology: JJVC contact lenses, design features, and associated benefits.

DECLARATION

DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.